Targeted anticytokine therapy and the failing heart

American Journal of Cardiology

Volumn 95, Issue 11 SUPPL. 1, 2005, Pages 9-16

  Mann, Douglas L ^a,b,c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c Winters Ctr for Heart Failure Res   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELSIDS; CYTOKINE ANTIBODY; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; MILRINONE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; PIPERANOMETOZINE; PREDNISONE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DEATH; DISEASE EXACERBATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOMODULATION; MEDICAL RESEARCH; MORTALITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT FAILURE;

EID: 19944386296     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.03.007     Document Type: Conference Paper

References (47)

1. E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, J.T. Willerson Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 2003 3133 3140
2. D.L. Mann, J.J.V. McMurray, M. Packer, K. Swedberg, J.S. Borer, W.S. Colucci, J. Dijan, H. Drexler, A. Feldman, L. Kober Targeted anti-cytokine therapy in patients with chronic heart failure results of the Randomized EtaNcercept Worldwide evALuation (RENEWAL) Circulation 109 2004 1594 1602
3. S. Kapadia, Z. Dibbs, K. Kurrelmeyer, D. Kalra, Y. Seta, F. Wang, B. Bozkurt, H. Oral, N. Sivasubramanian, D.L. Mann The role of cytokines in the failing human heart M. Crawford Cardiology Clinics 1998 WB Saunders Philadelphia 645 646
4. D.L. Mann Mechanisms and models in heart failure a combinatorial approach Circulation 100 1999 999 1088
5. B. Levine, J. Kalman, L. Mayer, H.M. Fillit, M. Packer Elevated circulating levels of tumor necrosis factor in severe chronic heart failure N Engl J Med 223 1990 236 241
6. G. Torre-Amione, S. Kapadia, C.R. Benedict, H. Oral, J.B. Young, D.L. Mann Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction a report from the Studies of Left Ventricular Dysfunction (SOLVD) J Am Coll Cardiol 27 1996 1201 1206
7. P. Aukrust, T. Ueland, E. Lien, K. Bendtzen, F. Muller, A.K. Andreassen, I. Nordoy, H. Aass, T. Espevik, S. Simonsen Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am J Cardiol 83 1999 376 382
8. A. Deswal, N.J. Petersen, A.M. Feldman, J.B. Young, B.G. White, D.L. Mann Cytokines and cytokine receptors in advanced heart failure an analysis of the cytokine database from the Vesnarinone Trial (VEST) Circulation 103 2001 2055 2059
9. G. Torre-Amione, S. Kapadia, J. Lee, J.B. Durand, R.D. Bies, J.B. Young, D.L. Mann Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart Circulation 93 1996 704 711
10. Y. Seta, K. Shan, B. Bozkurt, H. Oral, D.L. Mann Basic mechanisms in heart failure the cytokine hypothesis J Cardiac Fail 2 1996 243 249
11. C.R. Benedict, D.H. Weiner, D.E. Johnstone, M.G. Bourassa, J.K. Ghalli, J. Nicklas, P. Kirlin, B. Greenberg, M.A. Quinones, S. Yusuf Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction results of the Studies of Left Ventricular Dysfunction (SOLVD) registry J Am Coll Cardiol 22 1993 146A 153A
12. J.N. Cohn, T.B. Levine, M.T. Olivari, V. Garberg, D. Lura, G.S. Francis, A.B. Simon, T. Rector Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure N Engl J Med 311 1984 819 823
13. R. Ferrari, T. Bachetti, R. Confortini, C. Opasich, O. Febo, A. Corti, G. Cassani, O. Visioli Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure Circulation 92 1995 1479 1486
14. M. Rauchhaus, W. Doehner, D.P. Francis, C. Davos, M. Kemp, C. Liebenthal, J. Niebauer, J. Hooper, H.D. Volk, A.J. Coats Plasma cytokine parameters and mortality in patients with chronic heart failure Circulation 102 2000 3060 3067
15. 2 in patients with severe congestive heart failure treated with enalapril Circulation 96 suppl I 2000 I-322 [abstract]
16. L. Gullestad, P. Aukrust, T. Ueland, T. Espevik, G. Yee, R. Vagelos, S.S. Froland, M. Fowler Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure J Am Coll Cardiol 34 1999 2061 2067
17. A. Gurlek, M. Kilickap, I. Dincer, R. Dandachi, H. Tutkak, D. Oral Effect of losartan on circulating TNF-α levels and left ventricular systolic performance in patients with heart failure J Cardiovasc Risk 8 2001 279 282
18. T. Tsutamoto, A. Wada, T. Matsumoto, K. Maeda, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy J Am Coll Cardiol 37 2001 2086 2092
19. D.L. Mann Cytokines as mediators of disease progression in the failing heart J.D. Hosenpud B.H. Greenberg Congestive Heart Failure 1999 Lippincott Williams & Wilkins Philadelphia 212 232
20. D.L. Mann Inflammatory mediators and the failing heart past, present, and the foreseeable future Circ Res 91 2002 988 998
21. G. Torre-Amione, B. Bozkurt, A. Deswal, D.L. Mann An overview of tumor necrosis factor-α and the failing human heart Curr Opin Cardiol 14 1999 206 210
22. G. Baumgarten, P. Knuefermann, D.L. Mann Cytokines as emerging targets in the treatment of heart failure Trends Cardiovasc Med 10 2000 216 223
23. A. Deswal, A. Misra, B. Bozkurt The role of anti-cytokine therapy in the failing heart Heart Fail Rev 6 2001 143 151
24. S. Kapadia, G. Torre-Amione, T. Yokoyama, D.L. Mann Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNF-α in vitro Am J Physiol 37 1995 H517 H525
25. B. Bozkurt, S. Kribbs, F.J. Clubb Jr, L.H. Michael, V.V. Didenko, P.J. Hornsby, Y. Seta, H. Oral, F.G. Spinale, D.L. Mann Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats Circulation 97 1998 1382 1391
26. A. Deswal, B. Bozkurt, Y. Seta, S. Parilti-Eiswirth, F.A. Hayes, C. Blosch, D.L. Mann A phase I trial of tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc) in patients with advanced heart failure Circulation 99 1999 3224 3226
27. B. Bozkurt, G. Torre-Amione, M.S. Warren, J. Whitmore, O.Z. Soran, A.M. Feldman, D.L. Mann Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure Circulation 103 2001 1044 1047
28. M. Packer Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure J Card Fail 7 2001 176 182
29. Hughes S. Infliximab harmful in CHF: final results of ATTACH [American Heart Association Web site]. Available at: http://www.heart.org. Accessed June 12, 2002.
30. B.J. Scallon, M.A. Moore, H. Trinh, D.M. Knight, J. Ghrayeb Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions Cytokine 7 1995 251 259
31. J.W. Homeister, B.R. Lucchesi Complement activation and inhibition in myocardial ischemia and reperfusion injury Annu Rev Pharmacol Toxicol 34 1994 17 40
32. B. Klein, H. Brailly Cytokine-binding proteins stimulating antagonists Immunol Today 16 1995 216 220
33. A.F. Suffredini, D. Reda, S.M. Banks, M. Tropea, J.M. Agosti, R. Miller Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration J Immunol 155 1995 5038 5045
34. S.R. Weinberger, T.S. Morris, M. Pawlak Recent trends in protein biochip technology Pharmacogenomics 1 2000 395 416
35. J.I. Frishman, C.K. Edwards III, M.G. Sonnenberg, T. Kohno, A.M. Cohen, C.A. Dinarello Tumor necrosis factor (TNF)-α-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors J Infect Dis 182 2000 1722 1730
36. T.J. Evans, D. Moyes, A. Carpenter, R. Martin, H. Loetscher, W. Lesslauer, J. Cohen Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis J Exp Med 180 1994 2173 2179
37. C.P. Maury, A.M. Teppo Cachectin/tumour necrosis factor-alpha in the circulation of patients with rheumatic disease Int J Tissue React 11 1989 189 193
38. C.J. Fisher Jr, J.M. Agosti, S.M. Opal, S.F. Lowry, R.A. Balk, J.C. Sadoff, E. Abraham, R.M.H. Schein, E. Benjamin for the Soluble TNF Receptor Study Group Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein N Engl J Med 334 1996 1697 1702
39. M. Nakano, A.A. Knowlton, Z. Dibbs, D.L. Mann Tumor necrosis factor-α confers resistance to injury induced by hypoxic injury in the adult mammalian cardiac myocyte Circulation 97 1998 1392 1400
40. K. Kurrelmeyer, L. Michael, G. Baumgarten, G. Taffet, J. Peschon, N. Sivasubramanian, M.L. Entman, D.L. Mann Endogenous myocardial tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction Proc Natl Acad Sci U S A 290 2000 5456 5461
41. S. Lecour, R.M. Smith, B. Woodward, L.H. Opie, L. Rochette, M.N. Sack Identification of a novel role for sphingolipid signaling in TNF α and ischemic preconditioning mediated cardioprotection J Mol Cell Cardiol 34 2002 509 518
42. Wood S. Another trial with TNF blockade in CHF patients suspended [American Heart Association Web site]. Available at: http://www.heart.org. Accessed October 2, 2001.
43. A. Samuelsson, T.L. Towers, J.V. Ravetch Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor Science 291 2001 484 486
44. D.M. McNamara, R. Holubkov, R.C. Starling, G.W. Dec, E. Loh, G. Torre-Amione, A. Gass, K. Janosko, T. Tokarczyk, P. Kessler Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy Circulation 103 2001 2254 2259
45. L. Gullestad, H. Aass, J.G. Fjeld, L. Wikeby, A.K. Andreassen, H. Ihlen, S. Simonsen, J. Kjekshus, S. Nitter-Hauge, T. Ueland Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure Circulation 103 2001 220 225
46. G. Torre-Amione, F. Sestier, B. Radovancevic, J. Young Broad Modulation of Tissue Responses (Immune Activation) by Celacade May Favorably Influence Pathologic Processes Associated with Heart Failure Progression Am J Cardiol 95 suppl 2005 30C 37C
47. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, R.I. Fox, C.G. Jackson, M. Lange, D.J. Burge A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 1999 253 259